Maze Therapeutics, Inc. (MAZE)
| Market Cap | 1.41B +247.3% |
| Revenue (ttm) | 20.00M -88.1% |
| Net Income | -122.54M |
| EPS | -2.49 |
| Shares Out | 55.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 173,475 |
| Open | 24.66 |
| Previous Close | 24.86 |
| Day's Range | 24.66 - 25.77 |
| 52-Week Range | 9.83 - 53.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 62.55 (+146.07%) |
| Earnings Date | May 12, 2026 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $62.55, which is an increase of 146.07% from the latest price.
News
Maze Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The presentation highlighted progress in developing small molecule therapies for renal and metabolic diseases, with lead programs MZE829 and MZE782 advancing through clinical trials. Strong financials support a runway into 2029, enabling multiple data catalysts and pivotal studies in APOL1 kidney disease and PKU.
Maze Therapeutics Slides: Investor presentation
Maze Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patie...
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of…
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 202...
Maze Therapeutics Earnings release: Q1 2026
Maze Therapeutics released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Maze Therapeutics Quarterly report: Q1 2026
Maze Therapeutics has published its Q1 2026 quarterly earnings report on May 12, 2026.
Maze Therapeutics Proxy statement: Proxy filing
Maze Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Maze Therapeutics Proxy statement: Proxy filing
Maze Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50
The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based health...
Maze Therapeutics Slides: Corporate presentation
Maze Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
Maze Therapeutics Announces $150 Million Registered Offering
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its co...
Maze Therapeutics price target lowered to $64 from $68 at Truist
Truist lowered the firm’s price target on Maze Therapeutics (MAZE) to $64 from $68 and keeps a Buy rating on the shares. The firm has updated its outlook following the…
Maze Therapeutics price target raised to $58 from $52 at JPMorgan
JPMorgan raised the firm’s price target on Maze Therapeutics (MAZE) to $58 from $52 and keeps an Overweight rating on the shares. The firm cites an increased probability of success…
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze...
Maze Therapeutics falls -29.8%
Maze Therapeutics (MAZE) is down -29.8%, or -$14.60 to $34.40.
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James
Raymond James reiterates a Strong Buy rating and $56 price target on Maze Therapeutics (MAZE) after the company announced data from the ongoing Phase 2 HORIZON study of MZE829 in…
Maze Therapeutics falls -33.2%
Maze Therapeutics (MAZE) is down -33.2%, or -$16.28 to $32.72.
Leerink remains bullish on Maze, says Vertex comparison ‘apples to oranges’
Leerink says investors seem to be comparing Maze‘s (MAZE) MZE829 waterfall plot to the one seen with Vertex’s (VRTX) inaxaplin. The firm understands “the desire to compare assets,” though given…
Maze Therapeutics price target raised to $110 from $60 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Maze Therapeutics (MAZE) to $110 from $60 and keeps a Buy rating on the shares. The firm believes Maze’s Phase 2 HORIZON…
Maze Therapeutics reports Q4 EPS (65c), consensus (78c)
Cash, cash equivalents and marketable securities were $360.0 million as of December 31, 2025, compared to $196.8 million as of December 31, 2024. Maze expects that its current cash, cash…
Maze Therapeutics up 15% at $56.43 after Q4 results and MZE829 trial data
08:00 EDT Maze Therapeutics (MAZE) up 15% at $56.43 after Q4 results and MZE829 trial data
Maze Therapeutics announces positive topline data from Phase 2 HORIZON Trial
Maze Therapeutics (MAZE) “announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidne...
Maze Therapeutics Transcript: Study result
Phase II HORIZON data show MZE829 achieved a 36% mean reduction in proteinuria in broad AMKD, with 61.8% reduction in FSGS and 48.6% in non-diabetics. The drug was well-tolerated, and early diabetic data are promising. Plans are underway for a pivotal program.
Maze Therapeutics Press release: Study result
Maze Therapeutics issued a press release on March 25, 2026, disclosing material business information to investors.